Cargando…
Rivaroxaban plus aspirin vs. dual antiplatelet therapy in endovascular treatment in peripheral artery disease and analysis of medication utilization of different lesioned vascular regions
BACKGROUND: In the management of Peripheral Arterial Disease (PAD), the administration of anticoagulant or antiplatelet agents is imperative. The use of Dual Antiplatelet Therapy (DAPT) in conjunction with rivaroxaban has shown potential in mitigating adverse outcomes. Given the heterogeneity in the...
Autores principales: | Huo, SiYan, Cheng, Jun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10665835/ https://www.ncbi.nlm.nih.gov/pubmed/38026492 http://dx.doi.org/10.3389/fsurg.2023.1285553 |
Ejemplares similares
-
Edoxaban Plus Aspirin vs Dual Antiplatelet Therapy in Endovascular Treatment of Patients With Peripheral Artery Disease: Results of the ePAD Trial
por: Moll, Frans, et al.
Publicado: (2018) -
Endovascular Materials and Their Behavior in Peripheral Vascular Surgery
por: Mazzaccaro, Daniela, et al.
Publicado: (2022) -
Short vs prolonged dual antiplatelet treatment upon endovascular stenting of peripheral arteries
por: Kronlage, Mariya, et al.
Publicado: (2017) -
Cost-Effectiveness Analysis of Rivaroxaban Plus Aspirin Compared with Aspirin Alone in Patients with Coronary and Peripheral Artery Diseases in Italy
por: Ferrara, Pietro, et al.
Publicado: (2021) -
Commentary: Cost-Effectiveness Analysis of Rivaroxaban Plus Aspirin Compared With Aspirin Alone in Patients With Coronary and Peripheral Artery Diseases in Italy
por: Rawal, Shalin, et al.
Publicado: (2022)